info@marketresearchfuture.com   📞 +1 (855) 661-4441(US)   📞 +44 1720 412 167(UK)   📞 +91 2269738890(APAC)

SCHEDULE CALL

Anti-Nuclear Antibody (ANA) Testing Market Research Report By Test Type (Fluorescent Anti-Nuclear Antibody Test, Enzyme-Linked Immunosorbent Assay, Latex Agglutination Test, Western Blot Test), By End User (Hospitals, Diagnostic Laboratories, Research Institutes), By Indication (Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sjgren's Syndrome, Mixed Connective Tissue Disease), By Component (Reagents, Kits, Control Materials) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

Anti-nuclear Antibody (ANA) Testing Market

The Anti-nuclear Antibody (ANA) testing market will acquire a CAGR of 11.20 % and a value of US$1.44 Billion from 2022 to 2030.

Segmentation
By Type immunofluorescence enzymelinked immunosorbent assay
By Application Rheumatoid arthritis Systemic lupus erythematosus (SLE) Polymyositis Scleroderma Sjögren's syndrome and others
By End User Hospitals and clinics research laboratories and others
Key Players
Companies Profiled   Abcam plc. (US)    Alere (US)    Antibodies Inc.(US)    Bio-Rad Laboratories    Erba Diagnostics (US)    Indur Services    MBL INTERNATIONAL (US)    Merck KGaA (Germany)    Trinity Biotech (Republic of Ireland)
Drivers
Market Driving Forces   Increasing technological advancements    adoption of new techniques and increasing prevalence of various autoimmune diseases
report-list-img No. of Pages: 72
Report Code : MRFR/LS/2319-HCR
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

CLIENTS TESTIMONIALS